Shire Commits to Long-term Responsibility Goals in 2017 Annual Responsibility Review
CAMBRIDGE, Mass., March 22, 2018 /3BL Media/ – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the release of the Company’s 2017 Annual Responsibility Review. The Review, available at shire.com/responsibility outlines Shire’s new Responsibility strategy that includes ambitious long-term goals to be achieved by 2025, aimed at further enhancing the Company’s commitment to Responsibility and positively impacting patients, our employees, and our communities.
“Shire's enterprise-wide commitment to Responsibility is integral to our mission to serve the needs of patients and those who care for them,” said Flemming Ornskov, M.D., M.P.H., Shire’s Chief Executive Officer. “Our new Responsibility strategy was created to have a strong positive impact on our business and society – from serving patients, to supporting our communities, to protecting our environment.”
Shire has long been recognized for our commitment to Responsibility, including being listed on the FTSE4Good Index Series for positive environmental, social and governance practices since 2001. Shire’s Responsibility strategy lays out nine commitments that will enable the Company to do even more for patients, employees, and the global community. These commitments are aligned to three strategic Responsibility pillars: Supporting patients, People and culture, and Sustainable operations. The Annual Responsibility Review details the strategy’s commitments and goals, summarized as:
Supporting patients: We are committed to shortening the time to diagnosis for patients living with rare diseases. We aim to support patients and their families along their entire journey, including involvement in clinical trials and managing their care with innovative digital technologies.
People and culture: Equipping our employees for success is vital to serving our patients and communities. This includes providing a sense of purpose to what we do every day in a safe and inclusive environment that treats all people equally and fairly.
Sustainable operations: Managing sustainable operations means sourcing and manufacturing responsibly, delivering safe and effective medicines, and using natural resources carefully. This helps ensure our patients receive the treatments they need to lead healthier lives.
Additional information about Responsibility at Shire can also be found in Shire’s 2017 Annual Report, available at http://investors.shire.com/presentations-and-reports/ar-2017.aspx
For more information, please visit http://www.shire.com. Follow Shire on Social Media: Twitter, LinkedIn and YouTube.
For further information please contact:
Investor Relations
Christoph Brackmann
christoph.brackmann@shire.com
+41 795 432 359
Sun Kim
sun.kim@shire.com
+1 617 588 8175
Robert Coates
rcoates@shire.com
+44 203 549 0874
Media
Katie Joyce
kjoyce@shire.com
+1 781 482 2779
Elaine Salewske
elaine.salewske@shire.com
+1 847 323 8134
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.
